Jozef Madžo

4.4k total citations
52 papers, 1.5k citations indexed

About

Jozef Madžo is a scholar working on Molecular Biology, Hematology and Oncology. According to data from OpenAlex, Jozef Madžo has authored 52 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 39 papers in Molecular Biology, 15 papers in Hematology and 12 papers in Oncology. Recurrent topics in Jozef Madžo's work include Epigenetics and DNA Methylation (21 papers), RNA modifications and cancer (13 papers) and Acute Myeloid Leukemia Research (12 papers). Jozef Madžo is often cited by papers focused on Epigenetics and DNA Methylation (21 papers), RNA modifications and cancer (13 papers) and Acute Myeloid Leukemia Research (12 papers). Jozef Madžo collaborates with scholars based in United States, Czechia and Germany. Jozef Madžo's co-authors include Jaroslav Jelı́nek, Jean‐Pierre J. Issa, Jan Trka, Lucy A. Godley, Shinji Maegawa, Yue Lu, Shoudan Liang, Justin T. Lee, Charly R. Good and Shoghag Panjarian and has published in prestigious journals such as Nucleic Acids Research, Nature Communications and Journal of Clinical Oncology.

In The Last Decade

Jozef Madžo

50 papers receiving 1.4k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jozef Madžo United States 20 1.0k 226 222 213 201 52 1.5k
Sara Rollinson United Kingdom 13 824 0.8× 295 1.3× 234 1.1× 257 1.2× 144 0.7× 20 1.6k
Stefan Schmidt Austria 18 718 0.7× 215 1.0× 116 0.5× 257 1.2× 223 1.1× 40 1.4k
Matilde Y. Follo Italy 30 1.3k 1.2× 102 0.5× 523 2.4× 211 1.0× 180 0.9× 77 1.9k
Mondira Kundu United States 17 756 0.7× 91 0.4× 203 0.9× 252 1.2× 117 0.6× 28 1.3k
Kirsten Canté-Barrett Netherlands 17 529 0.5× 279 1.2× 240 1.1× 221 1.0× 92 0.5× 33 1.1k
Cinzia Sala Italy 25 708 0.7× 395 1.7× 238 1.1× 120 0.6× 73 0.4× 48 1.8k
Katsuhiko Takahashi Japan 20 611 0.6× 435 1.9× 62 0.3× 193 0.9× 71 0.4× 57 1.3k
Jiannong Cen China 17 554 0.5× 88 0.4× 359 1.6× 173 0.8× 168 0.8× 147 1.0k
Shinji Maegawa United States 16 1.0k 1.0× 76 0.3× 54 0.2× 272 1.3× 133 0.7× 33 1.4k
Kenji Kitajima Japan 19 642 0.6× 95 0.4× 153 0.7× 81 0.4× 94 0.5× 49 1.0k

Countries citing papers authored by Jozef Madžo

Since Specialization
Citations

This map shows the geographic impact of Jozef Madžo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jozef Madžo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jozef Madžo more than expected).

Fields of papers citing papers by Jozef Madžo

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jozef Madžo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jozef Madžo. The network helps show where Jozef Madžo may publish in the future.

Co-authorship network of co-authors of Jozef Madžo

This figure shows the co-authorship network connecting the top 25 collaborators of Jozef Madžo. A scholar is included among the top collaborators of Jozef Madžo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jozef Madžo. Jozef Madžo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Li, Huan, Srinivas Chatla, Xiaolei Liu, et al.. (2025). ZNF251 haploinsufficiency confers PARP inhibitors resistance in BRCA1-mutated cancer cells through activation of homologous recombination. Cancer Letters. 613. 217505–217505. 3 indexed citations
2.
Leu, Julia I-Ju, et al.. (2024). The Ashkenazi-Centric G334R Variant of TP53 is Severely Impaired for Transactivation but Retains Tumor Suppressor Function in a Mouse Model. Molecular and Cellular Biology. 44(12). 607–621. 1 indexed citations
3.
Kusic, Dara, et al.. (2024). ursaPGx: a new R package to annotate pharmacogenetic star alleles using phased whole-genome sequencing data. SHILAP Revista de lepidopterología. 4. 1351620–1351620. 2 indexed citations
4.
He, Shan, Tien D. Bui, Yuanyuan Tian, et al.. (2023). Tissue-infiltrating alloreactive T cells require Id3 to deflect PD-1–mediated immune suppression during GVHD. Blood. 143(2). 166–177. 6 indexed citations
5.
Golovine, Konstantin, Zhaorui Lian, Srinivas Chatla, et al.. (2023). ABL1 kinase as a tumor suppressor in AML1-ETO and NUP98-PMX1 leukemias. Blood Cancer Journal. 13(1). 42–42. 3 indexed citations
6.
Jeong, Hye Seon, et al.. (2023). DNA methylation entropy as a measure of stem cell replication and aging. Genome biology. 24(1). 27–27. 14 indexed citations
7.
Tanizawa, Hideki, Lisa Beatrice Caruso, Michael Hulse, et al.. (2022). The three-dimensional structure of Epstein-Barr virus genome varies by latency type and is regulated by PARP1 enzymatic activity. Nature Communications. 13(1). 187–187. 37 indexed citations
8.
Batchu, Sai, et al.. (2022). Transcriptome-guided resolution of tumor microenvironment interactions in pheochromocytoma and paraganglioma subtypes. Journal of Endocrinological Investigation. 45(5). 989–998. 6 indexed citations
9.
Panjarian, Shoghag, et al.. (2019). Abstract P3-05-03: Identification of epigenetically silenced breast cancer driver genes. Cancer Research. 79(4_Supplement). P3–5.
10.
Madžo, Jozef, et al.. (2019). The developmental origins of sex-biased expression in cardiac development. Biology of Sex Differences. 10(1). 46–46. 31 indexed citations
11.
Good, Charly R., Shoghag Panjarian, Andrew D. Kelly, et al.. (2018). TET1-Mediated Hypomethylation Activates Oncogenic Signaling in Triple-Negative Breast Cancer. Cancer Research. 78(15). 4126–4137. 108 indexed citations
12.
Hulse, Michael, Lisa Beatrice Caruso, Jozef Madžo, et al.. (2018). Poly(ADP-ribose) polymerase 1 is necessary for coactivating hypoxia-inducible factor-1-dependent gene expression by Epstein-Barr virus latent membrane protein 1. PLoS Pathogens. 14(11). e1007394–e1007394. 32 indexed citations
13.
He, Shan, Yongnian Liu, Lijun Meng, et al.. (2017). Ezh2 phosphorylation state determines its capacity to maintain CD8+ T memory precursors for antitumor immunity. Nature Communications. 8(1). 2125–2125. 93 indexed citations
14.
Jelı́nek, Jaroslav, et al.. (2017). Sex chromosomes drive gene expression and regulatory dimorphisms in mouse embryonic stem cells. Biology of Sex Differences. 8(1). 28–28. 42 indexed citations
15.
Sato, Takahiro, Matteo Cesaroni, Woonbok Chung, et al.. (2016). Transcriptional Selectivity of Epigenetic Therapy in Cancer. Cancer Research. 77(2). 470–481. 49 indexed citations
16.
Yamazaki, Jumpei, Jaroslav Jelı́nek, Yue Lu, et al.. (2015). TET2 Mutations Affect Non-CpG Island DNA Methylation at Enhancers and Transcription Factor–Binding Sites in Chronic Myelomonocytic Leukemia. Cancer Research. 75(14). 2833–2843. 67 indexed citations
17.
Chapman, Christopher G., Christopher J. Mariani, Feng Wu, et al.. (2015). TET-catalyzed 5-hydroxymethylcytosine regulates gene expression in differentiating colonocytes and colon cancer. Scientific Reports. 5(1). 17568–17568. 43 indexed citations
18.
Odenike, Olatoyosi, Anna B. Halpern, Lucy A. Godley, et al.. (2014). A phase I and pharmacodynamic study of the histone deacetylase inhibitor belinostat plus azacitidine in advanced myeloid neoplasia. Investigational New Drugs. 33(2). 371–379. 10 indexed citations
19.
Zuna, Jan, Ondřej Krejčí, Jozef Madžo, et al.. (2005). TEL/AML1 and immunoreceptor gene rearrangements—which comes first?. Leukemia Research. 29(6). 633–639. 3 indexed citations
20.
Madžo, Jozef, Jan Zuna, Kateřina Mužíková, et al.. (2002). Slower molecular response to treatment predicts poor outcome in patients with TEL/AML1 positive acute lymphoblastic leukemia. Cancer. 97(1). 105–113. 29 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Sara Rollinson Breakdown of academic impact, for papers by Stefan Schmidt Breakdown of academic impact, for papers by Matilde Y. Follo Breakdown of academic impact, for papers by Mondira Kundu Breakdown of academic impact, for papers by Kirsten Canté-Barrett Breakdown of academic impact, for papers by Cinzia Sala Breakdown of academic impact, for papers by Katsuhiko Takahashi Breakdown of academic impact, for papers by Jiannong Cen Breakdown of academic impact, for papers by Shinji Maegawa Breakdown of academic impact, for papers by Kenji Kitajima
Rankless by CCL
2026